(redirected from Claritin-d)
Also found in: Dictionary.


a nonsedating antihistamine (H1 receptor antagonist) used for treatment of allergic rhinitis and chronic idiopathic urticaria and as a treatment adjunct in asthma; administered orally.


Aerius (CA), Alavert, Allertin, Claritin, Claritin RediTabs, Clarityn (UK)

Pharmacologic class: Histamine1-receptor antagonist (second-generation)

Therapeutic class: Antihistamine (nonsedating)

Pregnancy risk category B


Selective histamine1-receptor antagonist. Blocks peripheral effects of histamine release during allergic reactions, decreasing or preventing allergy symptoms.


Syrup: 1 mg/ml

Tablets: 10 mg

Tablets (rapidly disintegrating): 10 mg

Indications and dosages

Seasonal allergies; chronic idiopathic urticaria

Adults and children ages 6 and older: 10 mg P.O. daily

Children ages 2 to 5: 5 mg P.O. daily

Dosage adjustment

• Renal or hepatic impairment


• Hypersensitivity to drug


Use cautiously in:
• renal or hepatic impairment
• elderly patients
• pregnant patients
• children younger than age 2 (safety not established).


• Give once a day on empty stomach.
• Place rapidly disintegrating tablet on tongue; give with or without water.
• Use rapidly disintegrating tablets within 6 months of opening foil pouch and immediately after opening individual tablet blister.

Adverse reactions

CNS: headache, nervousness, insomnia

EENT: conjunctivitis, earache, epistaxis, pharyngitis

GI: abdominal pain; dry mouth; diarrhea, stomatitis (in children)

Skin: rash, photosensitivity, angioedema

Other: tooth disorder (in children), fever, flulike symptoms, viral infections


Drug-food.Any food: increased drug absorption

Patient monitoring

• Watch for adverse reactions, especially in children.
• Assess patient's response to drug.
• Watch for new symptoms or exacerbation of existing symptoms.

Patient teaching

• Advise patient to take exactly as prescribed, once a day on empty stomach.
• Tell patient to report persistent or worsening symptoms.
• Instruct patient to report adverse reactions, such as headache or nervousness.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the foods mentioned above.


/lor·at·a·dine/ (lah-rat´ah-dēn) a nonsedating antihistamine used in the treatment of allergic rhinitis, chronic idiopathic urticaria, and asthma.


A nonsedating antihistamine, C22H23ClN2O2, used to treat allergic rhinitis and other allergic disorders.


a nonsedating antihistamine (H1-receptor antagonist) used for treatment of allergic rhinitis and chronic idiopathic urticaria and as a treatment adjunct in asthma, administered orally.


An ANTIHISTAMINE drug used to treat hay fever and other allergic disorders.


Any substance that reduces the effect of histamine or blocks histamine receptors, usually the histamine 1 (H1) receptor. It is used in the treatment of allergic conjunctivitis and also in the temporary relief of minor allergic symptoms of the eye. Common agents include antazoline sulfate, azelastine hydrochloride, cetirizine, chlorphenamine, emedastine, epinastine hydrochloride, ketotifen, levocabastine, loratadine and olopatadine. See hypersensitivity; mast cell stabilizers.


n brand name: Claritin;
drug class: antihistamine, H1 histamine antagonist;
action: acts on blood vessels, gastrointestinal system, respiratory system by competing with histamine for H1-receptor site; decreases allergic response by blocking histamine;
uses: seasonal rhinitis, allergy symptoms, idiopathic chronic urticaria.
References in periodicals archive ?
Investors are cautioned that all forward-looking statements involve risks and uncertainties, including but not limited to, the Company's ability to gain approval for its bioequivalent versions of Claritin-D 12 and Claritin Reditabs, Andrx's ability to manufacture and Perrigo's ability to market the Company's bioequivalent versions of Claritin D-24, Claritin-D 12 and Claritin Reditabs, as well as Andrx's results of operations.
Investors are cautioned that all forward-looking statements involve risks and uncertainties, including but not limited to Andrx's ability to manufacture, and Perrigo's ability to market, Claritin-D 24 as described herein as well as Andrx's results of operations.
Claritin-D 12 Hour, Claritin RediTabs and Claritin-D 24 Hour are registered trademarks of Schering-Plough Corporation.
In the case of Claritin-D 24, the underlying chemical entity patent expires on December l9, 2002, so the earliest any generic version of the product could receive FDA final marketing approval would be December 20, 2002.
They have built a strong franchise in CLARITIN and we are excited they chose us to assist as a manufacturing source to meet the demands for CLARITIN-D 12 Hour for the OTC market.
Under terms of the agreement, Schering-Plough has provided a license to a relevant patent pertaining to CLARITIN-D 24 Hour Extended Release Tablets to Impax.
Food and Drug Administration (FDA) had accepted the Company's filing of the ANDA for a generic version of Claritin-D 12-Hour Extended Release Tablets.
The once-daily formulations include tablets, syrup, orally disintegrating RediTabs, and Claritin-D 24-hour (loratadine I pseudoephedrine sulfate) extended-release tablets formulated with a decongestant.
IMPAX's application includes a certification under Paragraph IV of the Hatch-Waxman Amendments stating the company's belief that its product does not infringe Schering-Plough Corporation's listed patents on Claritin-D 12-Hour Extended Release Tablets.
Schering-Plough Corporation (NYSE:SGP) markets Claritin-D 24-Hour as an over-the-counter (OTC) drug for the relief of symptoms of seasonal allergic rhinitis (hay fever).
CLARITIN-D is available behind-the-counter in 12- or 24-hour extended release tablets and also includes the decongestant pseudoephedrine for powerful nasal congestion relief.